DURHAM, N.C., Sept. 4, 2015 (GLOBE NEWSWIRE) -- GeneCentric Diagnostics, Inc., a company devoted to changing the taxonomy of cancer through an integrated analysis of tumor pathology and genomics, today announced that it will present new data on its lung cancer subtyping product, LSP™ 120, at the 16th World Conference on Lung Cancer being held September 6-9, 2015 at the Colorado Convention Center in Denver, CO. LSP™ 120 was developed using GeneCentric's Cancer Subtyping Platform (CSP™), which provides precision medicine solutions for patient diagnosis and treatment, as well as advanced patient stratification in drug development and clinical trials.
Details of the presentation are as follows:
Title: "Survival Differences of Adenocarcinoma Lung Tumors with Squamous Cell Carcinoma or Neuroendocrine Profiles by Gene Expression Subtyping"
Session: Mini Oral 01 - Pathology
Date: Monday, September 7
Time: 10:45 a.m. to 12:15 p.m. MT
Location: Mile High Ballroom, 2c-3c, Colorado Convention Center
Presenter: Hawazin Faruki, DrPH, Vice President for Clinical Development, GeneCentric
"LSP™ 120 has the potential to identify a subset of lung adenocarcinoma patients with poor prognosis, as compared to other lung adenocarcinoma patients," said Dr. Faruki. "Reduced survival may be due to inherent features of the tumor and to variable response to standard lung adenocarcinoma therapeutic management. LSP™ 120 subtyping may prove to be an important tool in stratification strategies for improved drug trial design and patient care."
The World Conference on Lung Cancer is hosted by the International Association for the Study of Lung Cancer (IASLC). For more information on the event, visit: https://www.iaslc.org/events/16th-world-conference-lung-cancer.
GeneCentric Diagnostics, Inc. is a company devoted to changing the taxonomy of cancer through an integrated analysis of tumor pathology and genomics. GeneCentric is redefining the advanced classification of cancers through the development and commercialization of its proprietary Cancer Subtype Platform (CSP™). By capturing a comprehensive picture of DNA, RNA and copy number biomarkers, CSP™ can better enable drug developers and oncologists to make more individualized treatment decisions and meet the growing demand for precision medicines. GeneCentric's first application of CSP™ was launched with partner LabCorp® and is available as HistoPlusSM: Lung Cancer.
For more information, please visit www.genecentric.com.
CONTACT: Dr. Myla Lai-Goldman, CEO GeneCentric Diagnostics, Inc. +1-919-973-6544 firstname.lastname@example.org
Source:GeneCentric Diagnostics, Inc.